FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Thompson Jaye
 2. Date of Event Requiring Statement (Month/Day/Year)
09/24/2020		 3. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [GLSI]
(Last)
(First)
(Middle)
C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR, BUILDING 14		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
VP Clinical & Reg Affairs
 5. If Amendment, Date Original Filed(Month/Day/Year)
09/24/2020
(Street)

STAFFORD, TX 77477		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 252,810 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Thompson Jaye
C/O GREENWICH LIFESCIENCES, INC.
3992 BLUEBONNET DR, BUILDING 14
STAFFORD, TX 77477		       VP Clinical & Reg Affairs  

Signatures

/s/ Jaye Thompson 09/30/2020
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 3 is being amended to correct the prior Form 3 filed by the Reporting Person on September 24, 2020 which erroneously stated that the Reporting Person owned 140,450 shares of the Issuer's common stock. Includes a grant of 112,360 shares of the Issuer's common stock that vests as follows: 18,727 shares of common stock vested immediately upon grant, and the balance, or 93,633 shares of common stock vests in 36 equal installments on the 1st of every month with the first installment vesting on October 1, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.